Our findings identified that the UBE2J1/TRIM25-RPS3-NF-κB axis is a novel pathway mediated CRC proliferation and metastasis, providing a prospective therapeutic target for disrupting this pathway for CRC administration (Fig. 8). Here, NFKB1 is linked to colorectal carcinoma.